SCHEMBL25357485

SCHEMBL25357485

CC(C)n1nc(CC(=O)Nc2ccc3c(c2)[nH]c(=O)n3C)c(=O)c2ccc(Br)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 2/20 1.00
▸ MAPT P10636 1/20 0.36
▸ HTT P42858 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ERCC1 P07992 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ ERCC4 Q92889 1/20 0.35
▸ TERT O14746 5/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ NR2F2 P24468 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ NPY5R Q15761 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29492185 0.75 NLRP3 (0.64) NLRP3MEN1KMT2A
SCHEMBL29492036 0.75 NLRP3 (1.00) NLRP3NPY5R
SCHEMBL24077159 0.74 NLRP3 (0.59) NLRP3MAPTHTTMEN1KMT2A
SCHEMBL25356354 0.74 NLRP3 (0.64) NLRP3MAPTLMNASMN1; SMN2
SCHEMBL25431544 0.70 NLRP3 (0.59) NLRP3MEN1KMT2AALDH1A1LMNA
SCHEMBL31035885 0.70 NLRP3 (0.52) NLRP3MAPTHTTMEN1KMT2A
SCHEMBL25356861 0.69 NLRP3 (0.57) NLRP3HTTLMNA
SCHEMBL10386027 0.69 NLRP3 (0.51) NLRP3MAPTHTTMEN1KMT2A
SCHEMBL25356370 0.69 NLRP3 (0.53) NLRP3
SCHEMBL25359650 0.68 NLRP3 (0.51) NLRP3KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217346-B1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-07-02 — — EP disclosed
US-20230391756-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2023-12-07 — — US disclosed
EP-4217346-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
WO-2022063876-A1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed
EP-3974415-A1 NLRP3 MODULATORS Janssen Pharmaceutica NV (BE) 2022-03-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391756-A1 NEW COMPOUND NLRP3, NLRP1, IL1R1 NLRP3 1/4885MAPT 2596/4885HTT 3904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback